Financial Performance - The company's operating revenue for Q3 2023 was ¥75,863,078, a decrease of 35.41% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥4,944,453, down 42.88% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥886,273, a significant decline of 84.13% compared to the previous year[5]. - Total operating revenue for the third quarter was CNY 246,256,774.84, a decrease of 18.6% compared to CNY 302,488,326.43 in the same period last year[18]. - Net profit for the period was CNY 17,653,964.14, a decline of 18.5% from CNY 21,603,579.65 year-over-year[19]. - Earnings attributable to shareholders of the parent company were CNY 19,310,802.03, compared to CNY 22,487,953.15 in the previous year, representing a decrease of 14.5%[19]. - The company reported a basic and diluted earnings per share of CNY 0.24, down from CNY 0.28 in the same quarter last year[20]. Cash Flow and Liquidity - The net cash flow from operating activities was negative, with a net cash outflow of ¥24,166,610, contrasting with a positive cash flow of ¥27,158,690 in the same period last year[5]. - The net cash flow from operating activities for Q3 2023 was ¥24,166,611.22, a significant improvement compared to a net outflow of ¥27,158,694.67 in Q3 2022, indicating a turnaround in operational efficiency[23]. - Total cash inflow from investment activities was ¥289,500,862.76, up from ¥229,757,472.61 in the same period last year, reflecting increased investment recovery efforts[23]. - The net cash flow from investment activities was -¥90,574,587.49, an improvement from -¥156,733,060.83 in Q3 2022, suggesting better management of investment expenditures[23]. - Cash inflow from financing activities totaled ¥120,099,520.00, compared to ¥71,342,966.71 in Q3 2022, indicating a stronger capital raising effort[23]. - The net cash flow from financing activities was ¥68,782,756.37, a notable increase from ¥15,012,127.63 in the previous year, highlighting improved financial leverage[23]. - The total cash and cash equivalents at the end of Q3 2023 stood at ¥426,420,925.58, up from ¥311,890,955.77 at the end of Q3 2022, reflecting a healthier liquidity position[23]. - The company reported a decrease in cash paid for operating activities, totaling ¥316,279,234.73, down from ¥395,788,138.30 in Q3 2022, indicating cost control measures[23]. Assets and Liabilities - Total assets increased by 20.42% to ¥1,082,399,705.85 compared to the beginning of the year[5]. - The company's total assets as of September 30, 2023, amount to 1,082,399,705.85 yuan, an increase from 898,868,684.29 yuan at the beginning of the year[16]. - Current assets total 676,810,830.81 yuan, up from 647,426,048.56 yuan at the start of the year[16]. - The company's long-term equity investments rose by 47.43% to ¥122,243,237.41, attributed to increased external investments[9]. - Short-term borrowings rose to 176,194,024.21 yuan from 100,062,416.67 yuan[16]. - The total liabilities increased to CNY 256,665,251.80 from CNY 145,527,449.90, indicating a significant rise in financial obligations[19]. - The total number of common shareholders at the end of the reporting period is 10,843[12]. - The largest shareholder, Tibet Jiakang Times Technology, holds 58.35% of shares, totaling 46,677,966 shares, with 10,800,000 shares pledged[12]. Operational Efficiency and Expenses - Sales expenses decreased by 30.67% to ¥122,600,054.25, reflecting a decline in operating revenue[10]. - The company recorded a 39.89% increase in investment income, reaching ¥4,082,226.82, due to higher returns from financial investments[10]. - The company experienced a significant increase in government subsidies, with operating income from other sources rising by 1,824.92% to ¥751,765.65[10]. - Research and development expenses increased to CNY 14,753,007.10, up from CNY 13,101,570.92, indicating a focus on innovation[19]. Accounting and Reporting - The company has adopted new accounting standards starting in 2023, which resulted in a decrease in retained earnings by ¥73,320.45 due to deferred tax liabilities adjustments[24]. - The third quarter report was not audited, which may affect the reliability of the financial data presented[25].
多瑞医药(301075) - 2023 Q3 - 季度财报